8-K: Bio-Rad Announces Q4 and Full-Year 2024 Results, Initiates Restructuring Plan, and Offers to Acquire Stilla Technologies

Bio-Rad Laboratories reported a decrease in revenue for Q4 and full-year 2024, initiated a restructuring plan to improve operating performance, and announced a binding offer to acquire Stilla Technologies.

Summary

• Bio-Rad Laboratories announced its Q4 and full-year 2024 financial results on February 13, 2025.
• Q4 net sales decreased by 2.0% to $667.5 million compared to $681.2 million in Q4 2023.
• Full-year net sales decreased by 3.9% to $2,566.5 million compared to $2,671.2 million in the prior year.
• The Life Science segment experienced a decline in sales, while the Clinical Diagnostics segment saw a slight increase.
• The company reported a net loss of $715.8 million for Q4 and $1,844.2 million for the full year, primarily due to changes in the fair market value of its investment in Sartorius AG.
• Bio-Rad initiated a restructuring plan on February 7, 2025, expected to impact approximately 5% of its workforce and incur costs between $45 million and $50 million.
• The company anticipates recording $30 million to $35 million of restructuring charges in Q1 2025.
• Bio-Rad also announced a binding offer to acquire Stilla Technologies, a digital PCR developer, with the transaction expected to close by the end of Q3 2025.
• For full-year 2025, Bio-Rad expects non-GAAP, currency-neutral revenue growth of approximately 1.5% to 3.5% and a non-GAAP operating margin of approximately 13.0% to 13.5%.

Sentiment

Score: 5

Explanation: The announcement contains both positive and negative elements. The acquisition of Stilla Technologies and the projected revenue growth for 2025 are positive, but the revenue decline in 2024 and the restructuring plan are negative. The overall sentiment is neutral.

Positives

• The Clinical Diagnostics segment showed growth in both Q4 and full-year 2024, driven by increased demand for quality control and blood typing products.
• Bio-Rad is actively investing in product innovation and strategic partnerships to expand its Droplet Digital PCR platform.
• The acquisition of Stilla Technologies is expected to complement Bio-Rad's existing digital PCR portfolio and accelerate the development of next-generation solutions.
• The company is projecting non-GAAP, currency-neutral revenue growth of 1.5% to 3.5% for 2025.
• The company is projecting a non-GAAP operating margin of 13.0% to 13.5% for 2025.

Negatives

• Overall revenue decreased for both Q4 and full-year 2024.
• The Life Science segment experienced a significant decline in sales due to weakness in the biotech and biopharma end markets.
• The company reported a substantial net loss for both Q4 and full-year 2024, primarily due to changes in the fair market value of its investment in Sartorius AG.
• The restructuring plan will result in the elimination of approximately 5% of the workforce and incur significant costs.

Risks

• The company's ability to complete the restructuring plan within the anticipated timeline is uncertain.
• The impact of the workforce reduction on the company's business is a risk.
• Unanticipated charges may occur as a result of the restructuring plan.
• The acquisition of Stilla Technologies is subject to regulatory approvals and other closing conditions.
• The company's future financial performance is subject to various risks and uncertainties, including global economic conditions, competition, and product quality issues.

Future Outlook

Bio-Rad expects non-GAAP, currency-neutral revenue growth of approximately 1.5% to 3.5% and a non-GAAP operating margin of approximately 13.0% to 13.5% for full-year 2025.

Management Comments

• Norman Schwartz, Bio-Rad's Chairman and Chief Executive Officer, commented: Bio-Rad demonstrated resilience and adaptability in 2024.
• Mr. Schwartz continued: We begin 2025 in a strong position and remain committed to advancing our transformation, margin expansion, commercial excellence, and long-term shareholder value creation.
• Rmi Dangla, CEO of Stilla Technologies, stated, We are thrilled with the prospect of joining Bio-Rad, a leader in the field of digital PCR.

Industry Context

The life science and clinical diagnostics industries are experiencing ongoing evolution, with increasing demand for advanced technologies like digital PCR. Bio-Rad's acquisition of Stilla Technologies reflects a strategic move to strengthen its position in the digital PCR market and cater to the evolving needs of customers in research and clinical applications.

Comparison to Industry Standards

• Bio-Rad's revenue decline of 3.9% for the full year 2024 is worse than companies such as Danaher and Thermo Fisher Scientific who have seen growth in the same period.
• The restructuring plan to reduce workforce by 5% is similar to actions taken by other companies in the industry to improve efficiency and profitability.
• The acquisition of Stilla Technologies is comparable to other strategic acquisitions in the life science tools market, such as Agilent's acquisition of Resolution Bioscience, aimed at expanding product portfolios and market reach.
• Bio-Rad's projected non-GAAP operating margin of 13.0% to 13.5% for 2025 is lower than the operating margins of some of its larger competitors, such as Danaher and Thermo Fisher Scientific, which typically have operating margins in the range of 20% to 30%.

Stakeholder Impact

• Shareholders may be concerned about the revenue decline and net loss in 2024, but may be encouraged by the acquisition of Stilla Technologies and the projected revenue growth for 2025.
• Employees will be affected by the restructuring plan, which will result in the elimination of approximately 5% of the workforce.
• Customers may benefit from the acquisition of Stilla Technologies, which is expected to enhance Bio-Rad's digital PCR product portfolio and provide more comprehensive solutions.
• Suppliers may be affected by the restructuring plan, which could lead to changes in procurement and supply chain management.

Next Steps

• Complete the restructuring plan by the end of fiscal year 2025.
• Obtain regulatory approvals and complete the acquisition of Stilla Technologies by the end of Q3 2025.
• Integrate Stilla Technologies' products and technologies into Bio-Rad's existing portfolio.
• Launch the QX Continuum system.
• Focus on advancing transformation, margin expansion, commercial excellence, and long-term shareholder value creation.

Key Dates

Keywords

Bio-Rad, financial results, restructuring, acquisition, Stilla Technologies, digital PCR, life science, clinical diagnostics, revenue, net sales, operating margin